-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Scott Antonia, MD, PhD
Posted: May 27, 2019 Scott Antonia, MD, PhD, was appointed director of the newly formed DCI Center for Cancer Immunotherapy at Duke Cancer Institute. In addition to his leadership role, Dr. Antonia will also serve as professor of medical oncology. In his previous roles at H. Lee Moffitt Cancer Center, he built an active lung cancer…
-
PACIFIC Flooded Us with Optimism. Now What?
By Mirjana Rajer, MD, PhD Posted: April 1, 2019 For many years, the treatment of patients with stage III lung cancer has been a topic of intense debate among surgeons, radiation oncologists, and medical oncologists. Each discipline has eagerly expected new trials and results to make these discussions clearer and more optimistic. One of the most…
-
NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event
By Erik MacLaren, PhD Posted: April 1, 2019 On January 25, 2019, the Director of the National Cancer Institute (NCI) Norman E. Sharpless, MD, participated in a live social media event to discuss the NCI’s budget plans for 2019. During the hour-long discussion, Dr. Sharpless presented his assessment of the current funding situation, elaborated on his…
-
ICU Care for the Patient with Lung Cancer
By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care unit (ICU) have improved during the past 2 decades. In recent studies, ICU mortality for those patients admitted on an unscheduled basis was 30% to…
-
Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer
By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it make a difference in stage 1 nonsmall cell lung cancer? AATS 2018; Abstract 67. Pathologic upstaging of NSCLC occurs in an estimated 14% to 25% of…
-
Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC
Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have deeply changed the second-line treatment of patients with advanced NSCLC, with three newly registered drugs in only a few years. Immune checkpoint inhibitors are also…
-
Financial Incentives and Free Treatment Aids for Smoking Cessation in the Workplace
By Raymond Niaura, PhD Posted: April 1, 2019 IN REFERENCE TO: Halpern SD, French B, Small DS, et al.Randomized trial of four financial incentive programs for smoking cessation. N Engl J Med. 2015;372:2108-2117. Dr. Raymond Niaura As has been true for decades, smoking remains the leading cause of preventable morbidity and mortality in the United States.1…
-
Bringing Lung Cancer Screening into Communities: An NHS Pilot Program’s Success
By Richard Booton, MD, PhD, FRCP Posted: April 1, 2019 Dr. Richard Booton The symptomatic presentation of lung cancer is typically associated with advanced disease and poor survival. Screening asymptomatic at-risk individuals using low-dose CT (LDCT) reduces lung cancer–specific mortality by 20% to 26%,1 but challenges remain in ensuring participation of the most at-risk…
-
The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer
By Andre L. Moreira, MD Posted: April 1, 2019 Most of the progress in thoracic oncology is in the treatment of patients with NSCLC. The determination of subtypes of NSCLC, namely adenocarcinoma and squamous cell carcinoma, is directly linked with chemotherapy regimens and the search for targetable molecular alterations. The 2015 World Health Organization Classification of…
-
c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr. Karen Kelly
Posted: April 1, 2019 The first in-human study evaluating telisotuzumab vedotin (Teliso-V)—a c-MET antibody–drug conjugate formerly known as ABBV-399— has shown encouraging activity for patients with c-MET–positive NSCLC.1 Teliso-V combines the anti–c-MET monoclonal antibody ABT-700 (telisotuzumab) with monomethyl auristatin E, a cytotoxic antimicrotubule agent. Of the 48 patients enrolled, 35.4% had NSCLC and all were heavily…